ArticleInternational journal of endocrinology2025
The Long-Term Effects of Postoperative Radiotherapy in Acromegaly: Results From a Single-Center Acromegaly Registry in Iran.
Article in International journal of endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acromegaly is a rare but severe condition characterized by the excessive secretion of growth hormone (GH), leading to various metabolic alterations. Treatment options include surgery, pharmacotherapy, and radiotherapy (RT). RT can control the disease biochemically, either alone or in conjunction with medical therapy. This study aimed to evaluate the effectiveness of conventional RT in patients with postoperative acromegaly over a 15-year follow-up period, using specific cutoff criteria. Methods: A retrospective analysis was performed on 55 acromegaly patients who were monitored for an average of 15 (13.3-16.7) years and treated with conventional RT (median dose of 52 Gy) following pituitary surgery. Hormonal assessments included baseline and glucose-suppressed GH and IGF-1 levels, and side effects associated with RT were evaluated. Results: The baseline GH level decreased from 20.7 (16-25.4) μg/L to 11.2 (8.3-14.1) μg/L ( Conclusion: The results suggest that conventional RT is an effective long-term management strategy for patients who do not respond adequately to medical therapy or surgery. However, the high incidence of late-onset hypopituitarism must be taken into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.